Aquestive Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Aquestive Therapeutics, Inc. (AQST) reported Net Income (Loss) Available to Common Stockholders, Basic of -$61.38 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-14.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2019-03-14
- Aquestive Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2018-12-31 was -$13.94M.
- Aquestive Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2018-09-30 was -$15.04M, a 292.18% decline year-over-year.
- Aquestive Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2018-06-30 was -$36.49M.
- Aquestive Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2018-03-31 was $4.10M.
- Aquestive Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2018 was -$61.38M.
- Aquestive Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2017 was -$11.42M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$13.94M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$28.98M derived: sum of 2 quarters · filed 2019-03-14 | -$65.47M derived: sum of 3 quarters · filed 2019-03-14 | -$61.38M 10-K · filed 2019-03-14 |
| 2018-09-30 | -$15.04M 10-Q · filed 2018-11-06 | -$51.53M derived: sum of 2 quarters · filed 2018-11-06 | -$47.43M 10-Q · filed 2018-11-06 | -$58.10M derived: sum of 4 quarters · filed 2019-03-14 |
| 2018-06-30 | -$36.49M 10-Q · filed 2018-09-04 | -$32.39M 10-Q · filed 2018-09-04 | -$43.06M derived: sum of 3 quarters · filed 2019-03-14 | -$35.23M derived: sum of 4 quarters · filed 2019-03-14 |
| 2018-03-31 | $4.10M derived: 10-K 12 month − 3 quarters · filed 2019-03-14 | -$6.57M derived: sum of 2 quarters · filed 2019-03-14 | $1.26M derived: sum of 3 quarters · filed 2019-03-14 | -$5.25M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-12-31 | -$10.67M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$2.84M derived: sum of 2 quarters · filed 2019-03-14 | -$9.35M derived: sum of 3 quarters · filed 2019-03-14 | -$11.42M 10-K · filed 2019-03-14 |
| 2017-09-30 | $7.83M 10-Q · filed 2018-11-06 | $1.31M derived: sum of 2 quarters · filed 2018-11-06 | -$757.00K 10-Q · filed 2018-11-06 | |
| 2017-06-30 | -$6.51M 10-Q · filed 2018-09-04 | -$8.58M 10-Q · filed 2018-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |